Relapsed Refractory Solid Tumors clinical trials

Explore recruiting relapsed refractory solid tumors clinical trials.

Recruiting relapsed refractory solid tumors studies right now

Study details & eligibility ClinicalTrials.gov record
Study details & eligibility ClinicalTrials.gov record
Study details & eligibility ClinicalTrials.gov record
Study details & eligibility ClinicalTrials.gov record
Study details & eligibility ClinicalTrials.gov record
Study details & eligibility ClinicalTrials.gov record
Study details & eligibility ClinicalTrials.gov record
Study details & eligibility ClinicalTrials.gov record
Study details & eligibility ClinicalTrials.gov record
Study details & eligibility ClinicalTrials.gov record
Study details & eligibility ClinicalTrials.gov record
Study details & eligibility ClinicalTrials.gov record

Also recruiting in Europe

Relapsed Refractory Solid Tumors trials registered in the EU Clinical Trials Information System (CTIS). These are outside the "near me" matcher above - open a study for full details.

I3Y-MC-JPCS: A Phase 1b/2 Study of Abemaciclib in Combination with Irinotecan and Temozolomide (Part A) and Abemaciclib in Combination with Temozolomide (Part B) in Pediatric and Young Adult Patients with Relapsed/Refractory Solid Tumors and Abemaciclib in Combination with Dinutuximab, GM-CSF, Irinotecan, and Temozolomide in Pediatric and Young Adult Patients with Relapsed/Refractory Neuroblastoma (Part C).

Spain

Phase I and Phase II (Integrated)- Other EU CTIS Study details

A first-in-human, two-part, open-label, clinical study to assess the safety, tolerability, and activity of intravenous doses of ICT01 as monotherapy and in combination with an immune checkpoint inhibitor, in patients with advanced-stage, relapsed/refractory cancer (EVICTION Study)

Belgium, France, Spain, Germany

Phase I and Phase II (Integrated)- First administration to humans EU CTIS Study details

A Phase 1/2, first-in-human, two-part, open-label clinical trial of intravenous administration of CTL-002 given as monotherapy and/or in combination with an anti-PD-1 checkpoint inhibitor in subjects with advanced-stage, relapsed/refractory solid tumors.

Germany, Spain

Phase I and Phase II (Integrated)- Other EU CTIS Study details

LIGHTBEAM-U01 Substudy 01D: A Phase 1b/2 Substudy to Evaluate the Safety and Efficacy of Ifinatamab Deruxtecan in Pediatric Participants With Relapsed or Refractory Solid Tumors

France, Spain, Sweden, Germany, Italy, Belgium +1 more

Phase I and Phase II (Integrated)- Other EU CTIS Study details

Relapsed Refractory Solid Tumors trials by city

Relapsed Refractory Solid Tumors in Toronto Relapsed Refractory Solid Tumors in Vancouver Relapsed Refractory Solid Tumors in Montreal Relapsed Refractory Solid Tumors in Calgary Relapsed Refractory Solid Tumors in Edmonton Relapsed Refractory Solid Tumors in Ottawa Relapsed Refractory Solid Tumors in Winnipeg Relapsed Refractory Solid Tumors in Quebec City Relapsed Refractory Solid Tumors in Hamilton Relapsed Refractory Solid Tumors in Kitchener Relapsed Refractory Solid Tumors in London Relapsed Refractory Solid Tumors in Halifax Relapsed Refractory Solid Tumors in New York Relapsed Refractory Solid Tumors in Los Angeles Relapsed Refractory Solid Tumors in Chicago Relapsed Refractory Solid Tumors in Houston

Other conditions

Obesity Type 2 diabetes Type 1 diabetes Prediabetes Weight loss Metabolic syndrome High cholesterol High triglycerides High blood pressure PCOS Hypothyroidism Thyroid disease Gout Fatty liver disease (NAFLD/NASH) Heart failure Coronary artery disease Atrial fibrillation Stroke Stroke recovery Peripheral artery disease Pulmonary hypertension Deep vein thrombosis Chronic kidney disease Diabetic kidney disease